Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

PET/CT molecular imaging neuroendocrine differentiation prostate cancer

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
03 Jun 2022
Historique:
received: 16 03 2022
revised: 05 04 2022
accepted: 06 04 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 25 6 2022
Statut: epublish

Résumé

Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated.

Identifiants

pubmed: 35741197
pii: diagnostics12061387
doi: 10.3390/diagnostics12061387
pmc: PMC9221809
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339136
Clin Nucl Med. 2019 Jan;44(1):e28-e32
pubmed: 30394930
Clin Nucl Med. 2018 Apr;43(4):248-249
pubmed: 29474196
Front Oncol. 2015 Apr 14;5:90
pubmed: 25927031
J Cell Biochem. 2012 Feb;113(2):553-62
pubmed: 21938742
Cancers (Basel). 2021 Nov 17;13(22):
pubmed: 34830919
Cancers (Basel). 2019 Sep 20;11(10):
pubmed: 31547070
Nat Rev Urol. 2016 Apr;13(4):226-35
pubmed: 26902337
J Nucl Med. 2017 Sep;58(9):1452-1458
pubmed: 28280220
Cancer Res. 2016 Sep 1;76(17):4948-58
pubmed: 27302169
Eur Urol Oncol. 2019 Nov;2(6):670-676
pubmed: 31412006
Anticancer Res. 2010 Feb;30(2):369-74
pubmed: 20332441
J Clin Oncol. 2002 Jul 15;20(14):3072-80
pubmed: 12118020
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Eur J Cancer. 2019 Nov;121:7-18
pubmed: 31525487
Prostate. 2014 Aug;74(11):1153-9
pubmed: 24913988
Front Oncol. 2021 Jul 29;11:683793
pubmed: 34395251
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Endocr Relat Cancer. 2012 Oct 30;19(6):R187-204
pubmed: 22930558
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
Clin Nucl Med. 2017 Jan;42(1):1-6
pubmed: 27775942
Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205
pubmed: 33678552
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Asian J Urol. 2019 Jan;6(1):82-90
pubmed: 30775251
Clin Nucl Med. 2017 May;42(5):410-413
pubmed: 28240661
J Nucl Med. 2020 Jun;61(6):904-910
pubmed: 31806771

Auteurs

Joel Vargas Ahumada (J)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Sofía D González Rueda (SD)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Fabio A Sinisterra Solís (FA)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Quetzali Pitalúa Cortés (Q)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Liliana P Torres Agredo (LP)

Nuclear Medicine Department, Universidad Autónoma de Bucaramanga, Bucaramanga 680002, Colombia.

Jimenez Ríos Miguel (JR)

Urological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Anna Scavuzzo (A)

Urological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Irma Soldevilla-Gallardo (I)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Miguel A Álvarez Avitia (MA)

Medical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Nora Sobrevilla (N)

Medical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Francisco Osvaldo García Pérez (FO)

Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.

Classifications MeSH